In-stent Restenosis Nine Years after Initial Placement of a Drug-Eluting Stent

Drug-eluting stents (DES) represent a significant advance in the field of percutaneous coronary intervention with regard to target vessel revascularization and in reduction of flow limiting in-stent restenosis (ISR). Initially with percutaneous transluminal coronary angioplasty alone, ISR incidence was 32 –55% with only some improvement with bare metal stents (BMS) to 17–41%. DES have dramatically reduced the incidence of ISR to approximately 12% [1,2]. However, flow limiting in-stent restenosis (ISR) continues to be a clinical problem despite technological advances and improved understanding of the underlying mechanisms.
Source: Cardiovascular Revascularization Medicine - Category: Cardiology Authors: Source Type: research